Kennedy R. Lees
University of Glasgow
467 Papers
3.9K Citations
Kennedy R. Lees is an academic researcher from University of Glasgow. The author has contributed to research in topics: Stroke & Medicine. The author has an hindex of 86, co-authored 455 publications. Previous affiliations of Kennedy R. Lees include Ludwig Maximilian University of Munich & Cedars-Sinai Medical Center.
Chat about Author
Papers
Neuroprotection Is Unlikely to Be Effective in Humans Using Current Trial Designs: An Opposing View
TL;DR: To summarize recent neuroprotective trials, there has been no useful balance of benefit over risk, and the message is accurate: the drugs or doses the authors tried were inadequate.
46
The association of post‐stroke neurological improvement with risk of subsequent deterioration due to stroke events
Stella Aslanyan,Christopher J. Weir,C S Johnston,Michael Krams,Andrew P. Grieve,Kennedy R. Lees +5 more
TL;DR: This study confirms the association between recovery and subsequent neurological deterioration and is the first to indicate the greater importance of acute recovery at day 1 in comparison with later recovery.
46
Absolute risk and predictors of the growth of acute spontaneous intracerebral haemorrhage: a systematic review and meta-analysis of individual patient data
Rustam Al-Shahi Salman,Joseph Frantzias,Robert Lee,Patrick D. Lyden,Thomas W. K. Battey,A. Ayres,Joshua N. Goldstein,Stephan A. Mayer,Thorsten Steiner,Xia Wang,Hisatomi Arima,Hitoshi Hasegawa,Makoto Oishi,Daniel Agustin Godoy,Luca Masotti,Dar Dowlatshahi,David Rodriguez-Luna,Carlos A. Molina,Dong-Kyu Jang,Antoni Dávalos,J. Castillo,Xiaoying Yao,Jan Claassen,Bastian Volbers,S. Kazui,Yasushi Okada,Shigeru Fujimoto,Kazunori Toyoda,Qi Li,Jane Khoury,Pilar Delgado,José Álvarez Sabín,Mar Hernández-Guillamon,Luis Prats-Sánchez,Chunyan Cai,Mahesh Kate,R. McCourt,Chitra Venkatasubramanian,Michael N. Diringer,Y. Ikeda,Hans Worthmann,Wendy C. Ziai,Christopher D d'Esterre,Richard I. Aviv,Peter Raab,Yasuo Murai,Allyson R. Zazulia,Kenneth Butcher,S. Seyedsaadat,James C. Grotta,Joan Martí-Fàbregas,Joan Montaner,Joseph P. Broderick,Haruko Yamamoto,Dimitre Staykov,E. Sander Connolly,Magdy Selim,Rogelio Leira,Byung Moo Moon,Andrew M. Demchuk,Mario Di Napoli,Yukihiko Fujii,Craig S. Anderson,Jonathan Rosand,D. F. Hanley,Kenneth Butcher,Stephen M. Davis,Barbara A. Gregson,Kennedy R. Lees,Patrick D. Lyden,Stephan A. Mayer,A. W. Muir,Thorsten Steiner,Peng Xie,Babak Bakhshayesh,Mark McDonald,Thomas G. Brott,Paolo Pennati,Adrian R Parry-Jones,Craig J. Smith,S. Hopkins,Mark Slevin,V. Campi,Puneetpal Singh,Francesca Papa,Aurel Popa-Wagner,V. Tudorica,R. Takagi,A. Teramoto,Karin Weissenborn,Heinrich Lanfermann +90 more
TL;DR: In this large patient-level meta-analysis, models using four or five predictors had acceptable to good discrimination and could inform the location and frequency of observations on patients in clinical practice, explain treatment effects in prior randomised trials, and guide the design of future trials.
46
Aspirin Resistance and Compliance with Therapy
Jesse Dawson,Terry J Quinn,Mark Rafferty,Peter Higgins,Gautamanda Ray,Kennedy R. Lees,Matthew Walters +6 more
TL;DR: Aspirin resistance is common but poor compliance accounted for nearly half of cases of apparent aspirin "failure," suggesting objective measures to assess compliance are essential in studies of aspirin resistance.
45
Improving Trial Power Through Use of Prognosis-Adjusted End Points
TL;DR: Prognosis-adjusted end points can increase statistical power compared with fixed end points and Assessment is based on realistic goals for individual patients and yet trial results remain generalizable.
45